title: Role of positron emission tomography/computed tomography in breast cancer.
abstract: Although positron emission tomography (PET) imaging may not be used in the diagnosis of breast cancer, the use of PET/computed tomography is imperative in all aspects of breast cancer staging, treatment, and follow-up. PET will continue to be relevant in personalized medicine because accurate tumor status will be even more critical during and after the transition from a generic metabolic agent to receptor imaging. Positron emission mammography is an imaging proposition that may have benefits in lower doses, but its use is limited without new radiopharmaceuticals.
authors.affiliation: University of Tennessee Medical Center, 1924 Alcoa Highway, Knoxville, TN 37920, USA.
authors.forename: Austin C
authors.initials: AC
authors.lastname: Bourgeois
authors.forename: Lance A
authors.initials: LA
authors.lastname: Warren
authors.forename: Ted T
authors.initials: TT
authors.lastname: Chang
authors.forename: Scott
authors.initials: S
authors.lastname: Embry
authors.forename: Kathleen
authors.initials: K
authors.lastname: Hudson
authors.forename: Yong C
authors.initials: YC
authors.lastname: Bradley
mesh_terms: D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis / Q000000981:diagnostic imaging / Q000473:pathology; D009367:Neoplasm Staging; D057285:Precision Medicine; D011379:Prognosis; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: Breast cancer; Computed tomography; Positron emission mammography; Positron emission tomography